PredictImmune Ltd is a global biotechnology company that specializes in guiding personalized treatment for patients with immune-mediated diseases. Their technology, developed through over 15 years of research at the University of Cambridge, aims to improve outcomes for patients by providing tools for precision medicine in inflammatory diseases. They are focused on developing better disease management and improving the quality of life for patients with chronic diseases such as inflammatory bowel disease (IBD) and multiple sclerosis (MS).

Their flagship product, PredictSURE® IBD, is the world's first validated and CE-marked prognostic test for guiding treatment options in IBD. This simple blood-based biomarker test helps stratify adult patients by the risk of frequently relapsing disease, enabling early testing for optimal treatment choices. With a pipeline of tests in development, PredictImmune is committed to delivering the right treatment to the right patient at the right time